Iron Supplementation Improves Cardiovascular Outcomes in Patients with Heart Failure.

@article{Zhou2019IronSI,
  title={Iron Supplementation Improves Cardiovascular Outcomes in Patients with Heart Failure.},
  author={Xiaoping Zhou and Wei-ting Xu and Youjia Xu and Zhiyuan Qian},
  journal={The American journal of medicine},
  year={2019}
}
BACKGROUND Iron deficiency is prevalent in patients with heart failure. This meta-analysis was performed to evaluate the therapeutic effects of iron in patients with systolic heart failure and iron deficiency. METHODS We searched PubMed, Embase, and Cochrane databases through March 2018 and included 10 randomized controlled trials involving 1404 heart failure patients who underwent iron or placebo treatment. Odds ratio (OR) and weighted mean differences (WMD) were calculated using fixed- or… 
Iron Deficiency in Heart Failure Patients and Benefits of Iron Replacement on Clinical Outcomes Including Comorbid Depression.
TLDR
In essence, intravenous iron was found to be beneficial for New York Heart Association (NYHA) classification, quality of life measures, heart failure (HF) hospitalisation and aerobic capacity, while Oral iron however was not beneficial.
Effect of iron supplementation in patients with heart failure and iron deficiency: A systematic review and meta-analysis
TLDR
Oral or intravenous iron supplementation did not reduce mortality in iron deficient HF patients, however, intravenousIron supplementation was associated with a significant decrease in overall and HF hospitalizations.
Efficacy and safety of iron therapy in patients with chronic heart failure and iron deficiency: a systematic review and meta-analysis based on 15 randomised controlled trials
TLDR
Iron therapy reduces cardiovascular hospitalisation in patients with chronic heart failure with ID, and additionally improves cardiac function, exercise capacity and QoL in patientswith CHF with ID and anaemia, without an increase of adverse events.
Predictors of clinical improvement in heart failure patients with iron deficiency treated with ferric carboxymaltose
TLDR
FCM was useful to correct iron deficiency in clinical practice, independently to anemia, without relevant adverse effects, and clinical improvement was especially relevant in more symptomatic patients and those with absolute deficiency.
Intravenous Iron Decreases Rehospitalizations but Does not Change mortality in Patients Admitted with Acute Heart Failure and Iron Deficiency: A Systematic review and Meta-analysis
TLDR
I iron showed significant improvement in re-hospitalization rate for AHF hospitalizations in iron deficient patients but did not improve overall mortality.
Iron deficiency in heart failure: getting to the guidelines.
  • A. Lavoie
  • Medicine
    Current opinion in cardiology
  • 2020
TLDR
The purpose of this review is to explore the impact of iron deficiency on patients' quality of life and outcomes and how intravenous replacement, even in the absence of anemia, can improve these outcomes.
Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without Anemia.
TLDR
Iron deficiency, as captured by TSAT, is associated with higher risk of all-cause mortality and MACE in patients with nondialysis CKD, with or without anemia.
New treatment options to reduce heart failure hospitalization
TLDR
Two new meta-analyses support the application of sodium–glucose co-transporter-2 (SGLT2) inhibitors and intravenous iron to reduce hospitalization in chronic heart failure (HF) and report a state-of-the-art meta-analysis on the safety and efficacy of S GLT2 inhibitors in patients with HF.
Short‐term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial‐IRON trial
TLDR
This post hoc analysis evaluated whether treatment with FCM was associated with cardiac magnetic resonance changes in left and right ventricular function (LVEF and RVEF, respectively) at different points of systolic dysfunction.
Ferric carboxymaltose for the treatment of iron‐deficient heart failure patients: a systematic review and meta‐analysis
TLDR
An updated meta‐analysis of FCM's effect on hospitalizations and mortality remains unclear as previous randomized controlled trials (RCTs) and their meta‐analyses have been underpowered to detect significant differences.
...
1
2
3
...

References

SHOWING 1-10 OF 22 REFERENCES
The Efficacy and Safety of Iron Supplementation in Patients With Heart Failure and Iron Deficiency: A Systematic Review and Meta-analysis.
TLDR
Iron supplementation significantly reduced the risk of hospitalization for HF and the combined endpoint ofhospitalization forHF and death, without increasing therisk of adverse events in patients with symptomatic systolic HF and ID.
IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia.
TLDR
I.v. iron seems to be superior in improving functional capacity of heart failure patients, however, correction of anemia appears to be at least similar between p.o.o.'s iron and i.V. iron supplementation.
Iron deficiency: an emerging therapeutic target in heart failure
TLDR
In a series of placebo-controlled, randomised studies in patients with heart failure and iron deficiency, intravenous iron had a favourable effect on exercise capacity, functional class, LVEF, renal function and quality of life.
Changes in Echocardiographic Parameters in Iron Deficiency Patients with Heart Failure and Chronic Kidney Disease Treated with Intravenous Iron.
TLDR
Intravenous iron treatment was associated with improved myocardial functional parameters and cardiac dimensions in patients with anaemia and chronic kidney disease.
Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†
TLDR
Treatment of symptomatic, iron-deficient HF patients with FCM over a 1-year period resulted in sustainable improvement in functional capacity, symptoms, and QoL and may be associated with risk reduction of hospitalization for worsening HF.
Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial
TLDR
The results do not support use of oral iron supplementation in patients with HFrEF and iron deficiency, and high-dose oral iron did not improve exercise capacity over 16 weeks.
Iron deficiency: an ominous sign in patients with systolic chronic heart failure.
TLDR
In patients with systolic CHF, ID is common and constitutes a strong, independent predictor of unfavourable outcome, and iron supplementation may be considered as a therapeutic approach in these patients to improve prognosis.
The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the Studies Investigating Co-morbidities Aggravating Heart Failure.
TLDR
The impact of anaemia on reduced exercise capacity and on mortality is stronger than that of ID, and Anaemia remained an independent predictor of death after adjusting for clinically relevant variables.
Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency
TLDR
Treatment with intravenous FCM in patients with HF and iron deficiency improves iron stores and patients’ global assessment and functional class as assessed by the New York Heart Association improved on FCM versus standard of care.
Iron deficiency in chronic heart failure: an international pooled analysis.
TLDR
In this study, iron deficiency is common in patients with chronic HF, relates to disease severity, and is a strong and independent predictor of outcome.
...
1
2
3
...